Atara Biotherapeutics Stock (NASDAQ:ATRA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$10.61

52W Range

$6.50 - $39.50

50D Avg

$9.23

200D Avg

$12.44

Market Cap

$66.06M

Avg Vol (3M)

$148.73K

Beta

0.49

Div Yield

-

ATRA Company Profile


Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

165

IPO Date

Oct 16, 2014

Website

ATRA Performance


ATRA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 23Nov 04, 23 | 11:45 AM
Q3 22Nov 08, 22 | 9:43 PM
Q2 22Aug 08, 22 | 7:32 PM

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
XFORX4 Pharmaceuticals, Inc.
BTAIBioXcel Therapeutics, Inc.
VECTVectivBio Holding AG
MREOMereo BioPharma Group plc
FATEFate Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
TCRXTScan Therapeutics, Inc.
RCUSArcus Biosciences, Inc.
HOOKHOOKIPA Pharma Inc.
HRTXHeron Therapeutics, Inc.
KPTIKaryopharm Therapeutics Inc.
CRBUCaribou Biosciences, Inc.
ALLOAllogene Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
ITOSiTeos Therapeutics, Inc.